logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Discover
AGMB
AgomAb Therapeutics N.V. American Depositary Shares
15.00
1 x 14.75
1 x 15.32
bid
ask
+
0.00
0.00%
12:31 PM
timesize
Ytd2.39%
1y2.39%
14.64
day range
15.50
8.75
52 week range
17.82
Open15.10Prev Close15.00Low14.64High15.50Mkt Cap738.72M
Vol19.86KAvg Vol94.09KEPS-46.11P/E-0.33Forward P/EN/A
BetaN/AShort RatioN/AInst. OwnN/ADividendN/ADiv YieldN/A
Ex Div DateN/AEarningN/A50-d Avg12.29200-d Avg12.461yr Est0.00

AGMB News

Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
globenewswire.com
Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors

Antwerp, Belgium, August 10, 2026 - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab" or the "Company"

Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook
globenewswire.com
Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook

-- Regulatory alignment with U. S. Food and Drug Administration (FDA) on key elements of NOV-ERA Pha

Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease
globenewswire.com
Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Diseas

-- Regulatory alignment with U. S. Food and Drug Administration (FDA) on key elements of NOV-ERA Pha

This Apple Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday
benzinga.com
This Apple Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys

This Credo Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
benzinga.com
This Credo Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Mond

Top analysts changed ratings on top stocks, including Conexeu, CRDO, AGMB, SPCX, and FTH. See what a

AgomAb Therapeutics: High Risk, High Reward Stock
seekingalpha.com
AgomAb Therapeutics: High Risk, High Reward Stock

AgomAb Therapeutics offers high-risk, high-reward potential driven by two late-stage immunology drug

Agomab Announces Results of Annual General Meeting
globenewswire.com
Agomab Announces Results of Annual General Meeting

Antwerp, Belgium, May 27, 2026 - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab"), a clinical-stage

Agomab to Participate in Upcoming Conferences
globenewswire.com
Agomab to Participate in Upcoming Conferences

Antwerp, Belgium, May 14, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage

Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook
globenewswire.com
Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook

-- Cash and Cash Investments at December 31, 2025 of €116. 5 Million and Gross Proceeds of $208 Mill

Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis
globenewswire.com
Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of AL

Antwerp, Belgium, March 26, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“'Agomab'”), a clinical-st

Head to Head Review: AgomAb Therapeutics (NASDAQ:AGMB) vs. Prime Medicine (NASDAQ:PRME)
defenseworld.net
Head to Head Review: AgomAb Therapeutics (NASDAQ:AGMB) vs. Prime Medicine (NASDAQ:PRME)

Prime Medicine (NASDAQ: PRME - Get Free Report) and AgomAb Therapeutics (NASDAQ: AGMB - Get Free Rep

Prime Medicine (NASDAQ:PRME) & AgomAb Therapeutics (NASDAQ:AGMB) Critical Survey
defenseworld.net
Prime Medicine (NASDAQ:PRME) & AgomAb Therapeutics (NASDAQ:AGMB) Critical Survey

Prime Medicine (NASDAQ: PRME - Get Free Report) and AgomAb Therapeutics (NASDAQ: AGMB - Get Free Rep

Mattel Posts Downbeat Earnings, Joins Lyft, Robinhood And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
benzinga.com
Mattel Posts Downbeat Earnings, Joins Lyft, Robinhood And Other Big Stocks Moving Lower In Wednesday

Goodyear Tire Posts Downbeat Earnings, Joins BP, ON Semiconductor And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
benzinga.com
Goodyear Tire Posts Downbeat Earnings, Joins BP, ON Semiconductor And Other Big Stocks Moving Lower

Agomab Announces Closing of Initial Public Offering
globenewswire.com
Agomab Announces Closing of Initial Public Offering

ANTWERP, Belgium, February 9, 2026 (GLOBE NEWSWIRE) – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab

U.S. IPO Weekly Recap: 7 IPOs Make It One Of The Busiest Weeks In 4 Years
seekingalpha.com
U.S. IPO Weekly Recap: 7 IPOs Make It One Of The Busiest Weeks In 4 Years

Seven IPOs and six SPACs priced this week. Five IPOs and five SPACs submitted filings. Five IPOs are

Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
reuters.com
Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut

Shares of Agomab Therapeutics fell about 8% in their Nasdaq debut on Friday, valuing the Belgium-bas

Agomab Announces Pricing of Initial Public Offering
globenewswire.com
Agomab Announces Pricing of Initial Public Offering

ANTWERP, Belgium, February 5, 2026 (GLOBE NEWSWIRE) – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab

U.S. IPO Weekly Recap: Trio Of Sizable Listings Underwhelm To Close Out January
seekingalpha.com
U.S. IPO Weekly Recap: Trio Of Sizable Listings Underwhelm To Close Out January

U.S. IPO Weekly Recap: Trio Of Sizable Listings Underwhelm To Close Out January

AgomAb Therapeutics NV Readies US IPO On Early Promising Results
seekingalpha.com
AgomAb Therapeutics NV Readies US IPO On Early Promising Results

AgomAb Therapeutics is targeting chronic fibrotic diseases, advancing its lead candidate Ontuniserti